July 2024 – Page 41 – Goldea Capital

Vital Energy to Expand Delaware Basin Position Through Bolt-on Acquisition

Written by Customer Service on July 28, 2024. Posted in Mergers And Acquisitions.

Transaction highly accretive to key metrics; adds 68 high-return gross locations TULSA, OK, July 28, 2024 (GLOBE NEWSWIRE) — Vital Energy, Inc. (NYSE: VTLE) (“Vital Energy” or the “Company”) today announced the signing of a definitive joint purchase and sale agreement to acquire the assets of Point Energy Partners (“Point”), a Vortus Investments portfolio company. The transaction will significantly increase the Company’s operational scale and footprint in the Delaware Basin and add high-value development inventory. The agreement was signed in partnership with Northern Oil and Gas, Inc. (NYSE: NOG) (“NOG”). Under the terms of the agreement, the two companies will acquire Point Energy’s assets in an all-cash transaction for total consideration of $1.1 billion. Vital Energy agreed to...

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer’s Association Conference

Written by Customer Service on July 28, 2024. Posted in Public Companies.

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer’s disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups Benefits of blarcamesine on both amyloid-beta and brain volume, two underlying pathological hallmarks of Alzheimer’s disease EMA submission expected in Q4 NEW YORK, July 28, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous...

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Written by Customer Service on July 28, 2024. Posted in Public Companies.

Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Wa’el Hashad Wa’el Hashad, CEO, Longeveron – Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease – – Study meets its key objectives to advance data supporting favorable benefit/risk profile, support target engagement, and provide additional support for the efficacy profile of Lomecel-B™ – – Therapeutic potential demonstrated in MRI biomarker results showing 49% reduction in brain volume loss and improvement in inflammation featured in poster presentation – MIAMI, July 28, 2024...

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer’s Association International Conference® 2024 (AAIC®)

Written by Customer Service on July 28, 2024. Posted in Public Companies.

–INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)– –Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD– SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentation of a poster on baseline characteristics for the global INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD) at the Alzheimer’s Association International...

ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.

Written by Customer Service on July 27, 2024. Posted in Mergers And Acquisitions.

New York, July 27, 2024 (GLOBE NEWSWIRE) — NEW YORK, July 27, 2024 / GlobeNewswire/– Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027. Click here for more information https://monteverdelaw.com/case/alimera-sciences-inc/. It is free...

ALE INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and August 21, 2024 Shareholder Vote of ALLETE, Inc.

Written by Customer Service on July 27, 2024. Posted in Mergers And Acquisitions.

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) — NEW YORK, July 27, 2024 / GobeNewswire/– Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating ALLETE, Inc. (NYSE: ALE), relating to its proposed merger with a partnership led by Canada Pension Plan Investment Board and Global Infrastructure Partners. Under the terms of the agreement, ALLETE stockholders will receive $67.00 per share in cash for each share of common stock owned as of the closing of the transaction. THIS IS YOUR CHANCE TO ACT. The Shareholder Vote is scheduled for August 21, 2024. Click here for more information https://monteverdelaw.com/case/allete-inc/....

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger and Upcoming Vote on August 27, 2024, of Doma Holdings, Inc. – DOMA

Written by Customer Service on July 27, 2024. Posted in Mergers And Acquisitions.

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) — NEW YORK, July 27, 2024 / GlobeNewswire/– Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Doma Holdings, Inc. (NYSE: DOMA), relating to its proposed sale to Title Resources Group. Under the terms of the agreement, DOMA shareholders are expected to receive $6.29 in cash per share they own. THE TIME TO ACT IS NOW. The Shareholder Vote is scheduled for August 27, 2024. Click here for more information: https://monteverdelaw.com/case/doma-holdings-inc/. It is free and there is no cost or obligation to you. Before you hire a law firm, you should talk...

BALY INVESTIGATION: The M&A Class Action Firm Launches Investigation Merger of Bally’s Corp.

Written by Customer Service on July 27, 2024. Posted in Mergers And Acquisitions.

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) — NEW YORK, July 27, 2024 / GlobeNewswire/– Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Bally’s Corp. (NYSE: BALY), relating to its proposed merger with Standard General L.P. Under the terms of the agreement, Bally’s Corp stockholders will receive $18.25 in cash per share they own. Click here for more information https://monteverdelaw.com/case/ballys-corp/. It is free and there is no cost or obligation to you. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court? When was the last...

COFS ALERT: The M&A Class Action Firm Launches Investigation of the Merger of ChoiceOne Financial Services, Inc.

Written by Customer Service on July 27, 2024. Posted in Mergers And Acquisitions.

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) — NEW YORK, July 26, 2024 Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating ChoiceOne Financial Services, Inc. (Nasdaq: COFS), relating to its proposed merger with Fentura Financial, Inc. Under the terms of the agreement, ChoiceOne stockholders will receive 1.35 shares of Fentura stock per share of ChoiceOne stock they own. Click here for more information https://monteverdelaw.com/case/choiceone-financial-services-inc/. It is free and there is no cost or obligation to you. Before you hire a law firm, you should talk to a lawyer and ask: Do you file...

STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALT

Written by Customer Service on July 27, 2024. Posted in Mergers And Acquisitions.

NEW YORK, July 27, 2024 (GLOBE NEWSWIRE) — NEW YORK, July 27, 2024 / GlobeNewswire/– Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Calliditas Therapeutics AB (NASDAQ: CALT), relating to a tender offer from Asahi Kasei Corporation. Under the terms of the offer, Asahi Kasei Corporation will acquire all the outstanding shares of Calliditas stock for SEK 0.04 in cash per ADS. ACT NOW. The Tender Offer will expire on August 30, 2024. Click here for more information https://monteverdelaw.com/case/calliditas-therapeutics-ab/. It is free and there is no cost or obligation to you. Before...

Month: July 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice